This resource is a video abstract of a research paper created by Research Square on behalf of its authors. It provides a synopsis that's easy to understand, and can be used to introduce the topics it covers to students, researchers, and the general public. The video's transcript is also provided in full, with a portion provided below for preview:

"Real-world data and real-world evidence are terms widely used in the field of health care. In fact, various stakeholders are showing increasing interest in using real world data and real world evidence. Pharmaceutical companies, for example, use real world data for various purposes—from the early stages of development to post-launch. One hot topic focuses on using real world data and real world evidence to support regulatory decision making to deliver drugs faster to patients with high medical needs. This has been the subject of active discussion in the US, Europe, Japan and other countries, leading to regulatory reform and improvement of the implementation environment. However, there are barriers to the regulatory acceptance and use of both real world data and real world evidence. Real world data should be evaluated not only for quality but also for data relevance. There is a lack of universally accepted methodological criteria..."

The rest of the transcript, along with a link to the research itself, is available on the resource itself.

This resource is a video abstract of a research paper created by Research Square on behalf of its authors. It provides a synopsis that's easy to understand, and can be used to introduce the topics it covers to students, researchers, and the general public. The video's transcript is also provided in full, with a portion provided below for preview:

"Over the past few decades, the pharmaceutical industry has shifted its focus to areas of high unmet need Such as treating cancer and rare diseases For many of these conditions, traditional approaches to clinical trial design fall short The transition therefore calls for innovative clinical and regulatory strategies that can deliver new drugs fast Advanced digital technologies now offer unprecedented opportunities to improve drug development and, by extension, patients’ lives These include capturing patient-reported outcomes facilitating accelerated regulatory approval pathways analyzing real-world data and using intelligent analytics solutions While the tools and practices for unlocking the potential of innovation abound pharma is only in the early stages of adapting them at scale Aligning the needs of patients, providers, payers, and regulators will require biopharma organizations to adapt and evolve And leveraging digital tools, data, and analytics could help them get there Lee e.."

The rest of the transcript, along with a link to the research itself, is available on the resource itself.

These five modules introduce secondary science teachers to a powerful resource, from the Washington State Department of Health, entitled the “Washington Tracking Network” (WTN).  This is a tool for mapping (a) the distribution of numerous factors that influence public health, and (b) the inequitable distribution of health outcomes. This wonderful system naturally invites us to inquire about the intersections of biological, societal, and environmental issues. The overarching goal of these five  modules is to support teachers to design student activities that (1) inspire and connect students to real world health & environmental data, and each other, (2) promote clean air, land, and water, (3) promote the use of the Washington Tracking Network data mapping system, (4) support equitable, 3-dimensional learning, including the use of community wisdom to solve public health issues, and (5) use science for student action and leadership in response to current and historical misuses of science. These modules were created in collaboration with epidemiologists and communications professionals from the Washington Department of Health.